Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
61197-73-7
Molecular formula
C23H21ClN6O3
Molecular weight
464.9 g/mol
Drug class
Imidazobenzodiazepine hypnoticpositive allosteric modulator of GABAA receptors
Mechanism of action
Binds to the benzodiazepine site on GABAA receptor complexes and enhances the inhibitory effect of endogenous GABA, increasing chloride-channel opening and neuronal inhibition. This produces hypnotic, sedative, anxiolytic and anticonvulsant effects.
Indications / reported uses
Short-term treatment of insomnia, including difficulty initiating sleep and frequent nocturnal awakenings, when symptoms are severe, disabling or causing significant distress, under the current UK product information.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Loprazolam PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Loprazolam Permitted Daily Exposure (PDE) report (the Loprazolam PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Loprazolam Occupational Exposure Limit (OEL) report (the Loprazolam OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.